01 10Zyprexa
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 407
2019 Revenue in Millions : 419
Growth (%) : -3
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 430
2020 Revenue in Millions : 407
Growth (%) : 6
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 337
2021 Revenue in Millions : 430
Growth (%) : -22
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 1,695
2022 Revenue in Millions : 337
Growth (%) : 403
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,037
2014 Revenue in Millions : 940
Growth (%) : -9%
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -13.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 725
2015 Revenue in Millions : 940
Growth (%) : -23
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 581
2016 Revenue in Millions : 725
Growth (%) : -20
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 471
2017 Revenue in Millions : 581
Growth (%) : -19%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 419
2018 Revenue in Millions : 471
Growth (%) : -11
LOOKING FOR A SUPPLIER?